The impact of viral diseases has been profound. The influenza virus and human immunodeficiency virus (HIV) pandemics have demonstrated the enormous consequences of unchecked viral infections. However, these diseases represent only a small part of the problem. Of the sexually active Western population, 25-35% are infected with genital herpes ( Johnson et al., 1989) , genital warts are thought to afflict greater than 30% of the sexually active population in the US, there are 350 million carriers of hepatitis B virus (HBV) worldwide and 2% of the world's population are infected with hepatitis C virus (HCV). Many of these diseases are life-threatening and all greatly affect quality of life. The impact of viral diseases in the 21st century is destined to grow rather than decline.
Against this background it is not surprising that the growth in the number of therapies applied to antiviral diseases has been dramatic. Half of the new chemical entities introduced for the treatment of viral diseases during the 1983-1996 period have reached the market since 1994 (Bristol, 1997) . The effects of these new drugs against certain viruses have been very encouraging. The reduction in mortality in AIDS patients after treatment with combina-tion therapy including proteinase inhibitors has been particularly impressive (Pallella et al., 1998) (Fig. 1) .
These new therapies, while frequently aimed at different molecular targets, have been focused on a small number of viruses. Therefore, the opportunities for the development of further antiviral therapies are enormous. Various strategies have been used to discover and develop existing therapies. The aim of this review is to provide a historical background to the area, to describe the methods used to discover agents and to indicate promising new strategies. It is not the intention of the author to provide a comprehensive list of all currently available antivirals as such lists can be found elsewhere (Kinchington et al., 1997; Anonymous, 1998) .
Introduction
virus (Sneader, 1985a) . A decade of work culminated in the development of methisazone, introduced in 1960 for the prophylaxis of smallpox. In the epidemic in Madras in 1963, this compound demonstrated how effective chemotherapy could be for treating antiviral diseases; however, the introduction of vaccines soon after led to the eradication of the disease and made the compound redundant.
The foundations of antiviral research as a discipline were laid in the late 1960's (Galasso, 1998) when a select group of scientists declared that it might be possible to develop safe and effective medicines to combat viral diseases. This was not a commonly held view at the time since viruses were already known to use cellular host proteins for replication and therefore selectivity for virus over host was considered by many to be an insuperable problem.
The nucleoside analogue idoxuridine (Fig. 2 ) established that selectivity was achievable when it was found to be effective in treating herpesvirus infections in the eye (Kaufman & Heidelberger, 1964) . However, at that time it was felt to be an exception which escaped a more widespread problem of systemic toxicity simply through the iso- Ara-A (subsequently known as vidarabine; Fig. 2 ) was the first nucleoside analogue to be administered systemically and it founded the principle that an antiviral [against herpes simplex virus (HSV) and varicella-zoster virus (VZV)] could be administered in this way without generating serious toxicity for the host (Schabel, 1968; Buchanan & Hess, 1985) .
Acyclovir
The development of acyclovir (Fig. 2) for the treatment of herpesvirus infections in the late 1970's marked the 'coming of age' of antiviral therapy. It was the first example of a truly selective, efficacious antiviral drug. It was shown that the active entity is acyclovir triphosphate, which incorporates into nascent DNA chains, preventing further extension ( Fig. 3) (Sneader, 1985b) . The triphosphate also inhibits the viral DNA polymerase directly. The administered drug is initially converted to its monophosphate by a viral enzyme (thymidine kinase) and then to di-and triphosphate by host kinases. The viral enzyme carries out the initial phosphorylation of acyclovir about 200 times faster than host cell enzymes. This leads to higher concentrations of the active inhibitor in HSV-infected cells than in healthy ones and, therefore, to a high degree of selectivity (Levine, 1992a) . A second aspect of selectivity derives from the fact that the viral polymerase incorporates acyclovir triphosphate more readily than natural nucleoside phosphates. The success of acyclovir demonstrated that useful selectivity for viral enzymes over human host enzymes was a realistic target.
Zidovudine
HIV was recognized as the causative agent of the AIDS pandemic in the mid 1980s. A notable feature of the retrovirus family, of which HIV is a member, is the reverse transcriptase (RT) enzyme. This enzyme is essential for replication and has the unusual function of generating DNA from RNA and is therefore an attractive target for drug discovery. Nucleoside analogues once again proved to be effective inhibitors and zidovudine (AZT; Fig. 2 ) became the first licensed therapy for AIDS (Langtry & Campoli- , 1989) . AZT exerts its pharmacological effect by being incorporated into the growing DNA chain and preventing further growth. AZT triphosphate is the substrate for this function and is selective for HIV polymerase over equivalent mammalian enzymes. However, in the case of AZT, as with many nucleoside analogues, toxicity is still a problem. For AZT, high concentrations of the intermediate monophosphate are thought to cause the toxic effects and are formed as a result of the monophosphate being a poor substrate for the cellular thymidine monophosphate kinase. The underlying reasons for this poor enzymatic activity have now been the subject of detailed structural analysis and this work may enable improved compounds to be designed (Lavie et al., 1997) .
Richards

Fialuridine
A major problem with toxicity was encountered with the work on fialuridine (FIAU; Fig. 2 ). Here, promising activity was reported in models of HBV infection (Fried et al., 1992) . Initial dose-ranging studies in patients indicated a marked suppression of serum HBV levels but a sustained loss of viral DNA was achieved in only a few patients. Longer courses of treatment were suggested, and a 6 month trial begun. This trial had to be terminated on an emergency basis following acute toxicity which eventually led to the deaths of five patients (McKenzie et al., 1995) . Mitochondrial toxicity was suggested as a possible cause. This type of toxicity was known with other nucleoside analogues and was thought to be due to inhibition of mitochondrial DNA polymerase γ. The particularly acute toxicity demonstrated by FIAU may have been due to the presence of the 3′ hydroxyl, which would allow subsequent extension of DNA synthesis after incorporation of the modified nucleotide leading to defective chromosomal and mitochondrial DNA.
Lamivudine
A second generation of nucleoside analogues has now come to the fore. It was discovered that the unnatural enantiomer of some nucleoside analogues led to high potency against the target virus but with much lower cellular toxicity (Furman et al., 1995; Choi et al., 1991) . This principle led to lamivudine (3TC; Fig. 4 ) for the treatment of both HBV and HIV (Doong et al., 1991; Dienstag et al., 1995) .
Work continues on nucleoside analogues with the aim of finding greater therapeutic ratios (Krawczyk & Bischofberger, 1997) . However, the trend towards more modern methods of generating lead compounds provides a much more diverse range of molecular structures, leading to more opportunities for effective antiviral therapy. A cross-section of these methods will be discussed in the following sections of this review.
Current Strategies for Antiviral Drug Discovery
Although up to 1996, marketed antiviral therapies were dominated by nucleoside analogues, by the late 1980s new initiatives were beginning that would reduce this domination. Since the discovery of HIV, there has been a heightened awareness of antiviral research, even to the point of movies being made about the discovery of the virus. Antiviral research acquired a high profile, leading to increased investment in both the academic and industrial arenas.
The previous section described antivirals that were discovered by demonstrating inhibition of virus growth in replication assays or animal models. A precise knowledge of the molecular mechanism of inhibition was not required. Antiviral research has benefited enormously from the availability of molecular biology, the techniques of which have transformed virology, allowing viruses that were difficult to culture to become possible targets for therapy. The resultant understanding of virus life cycles at the molecular level has suggested many targets for intervention. These advances have allowed viral proteins to be produced in sufficient quantities to allow specific assays to be configured for high throughput screening. In addition, crystals suitable for structure determination can be grown. The previously employed holistic approach to inhibition of viruses in cell culture has given way to a reductionist approach, targeting specific viral enzymes and processes. As a result, the antiviral drug discovery paradigm has changed. It can now be broken down into a number of processes including target identification, lead generation (starting point for medicinal chemistry), lead optimization (improving activity, frequently in vitro) and lead development (completion of the optimization process to yield clinical candidates). These processes frequently use high throughput technologies and are often performed in parallel. The methods used in some of these steps will now be described in some detail together with examples of where they have been successfully employed.
Lead Generation
The majority of marketed drugs target one of two classes of biomolecules, enzymes and seven-transmembrane-span- ning-helices receptors (7TM or G protein-coupled receptors). To date the latter class have not been successfully exploited for antiviral therapies but this may change in the future since gene sequences expected to result in 7TM receptors have been identified in a herpesvirus (Ahuja & Murphy, 1993) and it has been postulated that entry of some viruses into cells may use this class of receptor (Ghorpade et al., 1998) . In general, enzymes have been the most common source of targets for antivirals; however, important classes of antiviral drugs, both marketed and in development, fall outside this category, for example amantadine (Shigeta, 1998) and the picornavirus canyon blockers (Diana & Pevear, 1997) . The generation of lead compounds is one of the key rate-determining steps in the drug discovery process. The strategies used to generate novel leads include substratebased (for enzymes), screening and biostructural (using high-resolution structural data of target biomolecules) approaches. Each of these strategies will be considered.
Substrate-based approaches
Molecular biological techniques have enabled the isolation of many, previously unavailable, active viral enzymes. The natural substrate or a synthetic variant can be prepared and together they can form the basis of an assay for enzyme activity and its inhibition. Such assays are frequently quantitative and provide accurate data for the monitoring of activities of inhibitors and understanding the kinetics of the processes involved. The substrate clearly represents a mole-cule which interacts with the enzyme, and as such forms not only the basis of the assay, but a lead structure. This type of approach has been applied to several antiviral targets.
HIV proteinase inhibitors. The genetic information for the structural proteins and major enzymes of HIV is encoded in three distinct genes: gag, pol and env. On the basis of the nucleotide sequence it was postulated that the pol open reading frame might encode a proteinase which, by analogy with other retroviruses, might be responsible for cleaving the initially formed polyprotein into the functional and structural proteins required to complete the virus life cycle. Site-directed mutagenesis provided evidence that the proteinase was absolutely required for processing the polyprotein and also suggested that the enzyme was essential for the production of infectious virus particles (Martin et al., 1995) .
Amino acid sequence information suggested that the enzyme was a member of the aspartyl proteinase family. Significant differences existed between the proposed viral enzyme and other mammalian members of this enzyme class, such as renin. The mammalian enzymes have two aspartic acid residues which make up a key component of the catalytic machinery. Renin is much larger than the sequence assigned to the viral proteinase, where only one key aspartic acid residue could be identified. This information led to the key conclusion that the virus encodes a protein which dimerizes to form a functional enzyme (Pearl & Taylor, 1987). A variety of cleavage sites are present within the HIV polyproteins but alignment of the sequences around these sites revealed a consensus from three of them with phenylalanine and proline residues around the cleavage site. This particular sequence seemed appropriate for the drug discovery programme because cleavage at such a position is, at best, a rare event for mammalian endopeptidases.
The similarities of HIV proteinase to renin allowed medicinal chemistry research aimed at finding inhibitors to capitalize on the information gained from renin inhibitor projects. Notably, transition state mimetics were used to achieve isolated enzyme activity (Pauling, 1946) . Systematic modification of these structures led to saquinavir ( Fig. 5 ), an inhibitor with sub-nanomolar activity versus the enzyme (Roberts et al., 1990) . This compound also demonstrated high selectivity for HIV proteinase over other aspartyl proteinases and antiviral activity in cell culture assays. It was subsequently shown to reduce circulating virus in clinical trials and became the first marketed HIV proteinase inhibitor in 1995.
This example illustrates how rapidly clinical candidates can be discovered using the substrate-based approach. The principal potential disadvantage of this approach is the inevitable similarity of the inhibitors to the peptide substrate, which has led to suboptimum pharmacokinetic properties.
An extension of the substrate-based approach utilized an unusual feature of HIV proteinase. The homodimeric nature of the enzyme led to the suggestion that symmetrical inhibitors might be effective (Kempf et al., 1990) . Two types of inhibitor were prepared, differing in the origin of symmetry ( Fig. 6 ). Both classes of compound led to inhibitors of the enzyme which were effective at low nanomolar concentrations. One of the postulated advantages of this approach was selectivity, as the symmetry demonstrated by the viral enzyme was unique; the resulting inhibitors did indeed demonstrate high levels of selectivity.
Influenza virus neuraminidase inhibitors. The influenza virus pandemics of the 20th century have demonstrated the enormous, acute effect that can be exerted by this family of highly infectious viruses (Levine, 1992b) . Amantadine (Fig. 2) (Davies et al., 1964) and the closely related molecule rimantadine (Wintermeyer & Nahata, 1995) were active against these viruses although they were shown to be effective only against influenza A virus and inactive against influenza B virus. Amantadine is known to cause sideeffects and is subject to the generation of rapid viral resistance (Wade, 1997) and so there were clear opportunities for drugs with improved target profiles. The early influenza antivirals were identified empirically using cell culture assays (Davies et al., 1964) but since then the viruses have become the subject of much study and the structures of the crucial virus envelope proteins neuraminidase (Colman et al., 1983) and haemagglutinin (Wilson et al., 1981) have been solved by X-ray crystallographers.
Early studies on the neuraminidase enzyme identified a derivative of neuraminic acid as a modest inhibitor of the enzyme (Fig. 7) (Meindl et al., 1974) . This compound was identified as a transition state-like inhibitor using biochemical techniques (Chong et al., 1991) and this was subsequently confirmed by X-ray crystallography (Bossart-Whittaker et al., 1993) . Potent inhibitors of the neuraminidase enzyme have been designed using this transition state inhibitor and the crystal structure as a starting point. Analysis of this crystal structure identified a site and the type of modification required to increase potency: replacement of a hydroxyl by an amino group. Replacement of the hydroxyl by the more basic guanidinyl group was postulated to increase the binding further. Preparation of these compounds fully vindicated the lead generation strategy, producing highly potent inhibitors of the enzyme (von Itztein et al., 1993) and this approach has resulted in zanamavir (GG167), currently in the late stages of clinical development (Bethell & Smith, 1997) . This compound lacks appreciable oral activity but can be dosed intranasally. The development of GS4104 (Li et al., 1998) , the ester prodrug of GS4017 (Kim et al., 1997) , addressed the lack of oral activity of GG167. GS4104 is a carbocyclic analogue of sialic acid; it was rationalized that the carbon-carbon double bond mimics the oxonium species assumed to be generated as the transition state in the enzymatic cleavage. Another key difference between the two classes of compounds was the use of a lipophilic side chain in GS4071 rather than the hydrophilic glycerol side chain used in GG167. X-ray crystallographic data indicated that one of the hydroxyls in the glycerol side chain did not interact with the active site of the enzyme, although the other two hydroxyls on this side chain made hydrogen bonds to glutamic acid residue 276. Also, one of the methines of the side chain formed a hydrophobic contact with the hydrocarbon chain of arginine 224. A systematic investigation of this area of the molecule was carried out.
This work proved especially productive and uncovered a modified lipophilic binding site which could be exploited to generate high potency compounds lacking the guanidino moiety which had been key to the initial series of inhibitors. X-ray crystallographic data revealed an explanation for this observation: the two classes of compound use similar binding modes for key carboxyl and nitrogen interactions on the carbocyclic or pyran ring, but the lipophilic binding site is formed by the side chains of residues 276, 224 and 222 and the polar head groups of residues 276 and 224 now interact together ( Fig. 8 ).
Screening approach
The second general strategy for obtaining lead compounds is by screening libraries of compounds. Over the last 15 years huge advances have been made using this technique. While many of the early chemical leads for antiviral research were discovered using random screening approaches, the notion of systematic screening of hundreds of thousands of compounds was not envisaged. This is now an accepted and invaluable part of the process of lead generation.
HIV RT inhibitors. Nucleoside inhibitors of the RT enzyme of HIV, such as AZT, were the first class of anti-HIV drug. The toxicity associated with these compounds and the problem of drug resistance led to the search for alternative classes of compound. One clear way of generat- 
ing novel lead structures is to screen libraries of compounds. The techniques used have evolved considerably. Initially, smaller libraries were screened against virus in culture. This led to the HEPT compounds (Baba et al., 1989) and to the TIBO class of non-nucleoside RT inhibitors (NNRTI), such as tivirapine ( Fig. 9 ) (Pauwels et al., 1990) . Nevirapine was also discovered using a screening approach to evaluate large numbers of compounds but, in this case, against the isolated enzyme (Merluzzi et al., 1990) .
Nevirapine has now progressed to market, although its use is limited to a component in combination therapy due to the rapid emergence of resistance. Further classes of NNRTI have also been discovered, for example delavirdine (Romero et al., 1991) . It is intriguing to note that despite their apparent structural diversity and random origin it has been demonstrated that many bind in the same region on the enzyme away from the active site and exert their action through allosteric inhibition .
HIV proteinase inhibitors. High throughput screening has also been employed successfully to discover inhibitors of HIV proteinase. The compounds that have been identified have novel structures and very different physicochemical properties from the peptide-based compounds typical of the substrate-based approach. A class of pyranones with activities at the 1 µM level was identified from initial screening ( Fig. 10 ) (Prasad et al., 1994) . Optimization of this lead structure utilized X-ray crystallographic data. Key features of the pyranone were the phenyl substituent which occupied the aromatic P1 binding pocket, a benzyl substituent that occupied the P1′ binding pocket and the hydroxyl which bound to the two aspartyl residues. Further optimization led to highly potent inhibitors (Prasad et al., 1995) . High throughput screening also demonstrated that warfarin weakly inhibited HIV proteinase. Based on this observation, related compounds were screened, resulting in phenprocoumon, which had significantly improved but still weak activity (Thaisrivongs et al., 1994) . Once again crystallographic data of a complex of this inhibitor bound to the enzyme was used to optimize the structure and to create highly potent compounds. Despite the fact that different compound libraries were used in the two examples above, very similar structures were isolated. Another example of this type of convergence has been observed for HSV helicase inhibitors (Fig. 11) (Liuzzi et al., 1998; Spector et al., 1998) . This repetition seems surprising, given the very large number of compounds screened and gives some indication of the sensitivity of some enzymes to the precise structures of inhibitors. In one of these examples an optimized structure with inhibitory activity against HSV helicase in the low nanomolar range has been reported.
Influenza virus polymerase inhibitors. Influenza virus has also been a target for high throughput screening approaches. Several classes of compounds have been identified that inhibit the polymerase formed by an assembly of virus proteins. A series of 4-substituted 2,4-dioxobutanoic acids was identified which inhibited the endonuclease activity of the polymerase. These compounds also inhibited the replication of influenza A and B viruses in cell culture (Tamassini et al., 1994) . The same group reported another compound, flutimide, which had a similar profile of activity but was obtained from screening natural products (Tomassini et al., 1996) . A further report of inhibition of the endonuclease activity resulting from screening described N-hydroxamic acids and N-hydroxyimides (Cianci et al., 1996) . HIV Tat-TAR inhibitors. The screening approach has further evolved by enriching the libraries with compounds produced using parallel synthesis. This process has been illustrated for the preparation of inhibitors of the HIV Tat-TAR interaction (Hamy et al., 1997) . Here, 3.2 million peptides were used as the starting point; sequential deconvolution of this library led to the identification of a 12 nM peptide which binds to the TAR RNA. A similar approach has been reported for HIV integrase inhibitors (Lutzke et al., 1995) . The current trend is towards using libraries of low molecular weight, non-peptidic compounds (Patel & Gordon, 1996) .
Biostructural approach
The third strategy for generating lead compounds is the biostructural approach. Here, high-resolution structural data on target biomolecules are used to design lead compounds. To date, this type of de novo design of inhibitors from the crystal structure alone has met with very limited success, although some reports of leads generated in this way have appeared (Desjarlais et al., 1990) . As illustrated above, once a co-crystal with a ligand bound to the target structure is available, the chances of success for a designed inhibitor are considerably enhanced. This difference is largely due to the lack of a quantitative understanding of the intermolecular interactions leading to binding. However, coupled with this has been the lack of availability of crystal structures during the early stages of projects. This position is clearly changing. It is evident from the current literature that crystal structures of several important targets are available before reports of compounds in development, including human cytomegalovirus (HCMV) proteinase (Qui et al., 1996; Shieh et al., 1996; Tong et al., 1996; Ping et al., 1996) , VZV proteinase (Qui et al., 1997) , HCV NS3 proteinase (Kim et al., 1996; Love et al., 1996) , HCV NS3 helicase (Yao et al., 1997; Kim et al., 1998) , rhinovirus 3C proteinase (Matthews et al., 1994) and HIV integrase (Dyda et al., 1994) . This structural information may provide a more detailed insight into the mechanism of action of the enzymes. While sequence data can often identify the class of enzyme, it is becoming evident that viruses have evolved highly efficient methods of exerting control over their enzymes to ensure the catalysed processes occur in the right order, on the right substrate and in the right place within the cell (Babe & Craik, 1997 ). An understanding of the details of these control processes may well be essential for the discovery of potent inhibitors or, alternatively, provide novel approaches to inhibition. In the case of HCV proteinase it had been predicted that it belongs to the chymotrypsin class of serine proteinases characterized by two β-barrels in the tertiary structure. However, improved catalytic activity is observed when the cofactor NS4A is present. This requirement has been explained by the crystal structure where it is apparent that part of NS4A supplies one of the β-strands of one of the β-barrels. The herpesvirus proteinases, although classified as serine proteinases because they use a nucleophilic serine to initiate protein cleavage, exhibit sequence homology across the virus family but demonstrate very little with other serine proteinases. The crystal structures of two members of herpesvirus proteinase family (HCMV and VZV)
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The optimization of one of these compounds resulted in analogues active at nanomolar concentrations. show that they both belong to a new class of proteinase which has an entirely novel protein fold and a catalytic triad consisting of a serine and two histidines rather than a serine, histidine and aspartate. It will be interesting to observe the impact that these data have on the drug discovery process.
Other difficulties associated with the de novo design of inhibitors can be illustrated with the NNRTIs. Here, crystal structures of several inhibitors complexed to the enzyme have been reported Esnouf et al., 1995) . It can be seen from this work that the binding site for the inhibitors is formed by movements in the side chains of amino acids making up the protein and is not present in the structure of the apoenzyme. Therefore, identifying the binding site in the absence of the inhibitors would be exceptionally difficult. Accurate computational methods to predict the internal mobility of proteins do not exist at present but this is an area of active research (Wagner, 1995) .
Alternative methods
HSV ribonucleotide reductase inhibitors. Where association of two or more subunits is required for a functional enzyme, in theory, inhibition can be achieved by designing compounds which prevent this association. However, inhibition of protein-protein interactions of this type has proved an extremely difficult approach, although notable examples are now starting to appear from other areas of drug discovery. Within the antivirals field the attempt to inhibit ribonucleotide reductase marks a significant advance. HSV encodes this enzyme to provide the high levels of deoxynucleotides required for replication of viral DNA in infected cells. The functional enzyme is formed by the reversible association of two distinct homodimeric units. The C terminus of the small subunit is critical for the association and lead inhibitors were synthesized which consisted of these C terminal residues. These compounds were designed to mimic and interfere with the interactions of the small and large units, prevent association and hence inhibit the enzyme (Moss et al., 1995) .
Very impressive results were obtained during the optimization of these inhibitors, leading to highly potent compounds ( Fig. 12) (Moss et al., 1996a) . These compounds demonstrated activity in a replication assay against HSV-1, HSV-2 and acyclovir-resistant HSV strains in cell culture, and were also active in vivo when administered topically as an ophthalmic cream in an ocular model (Liuzzi et al., 1994; Brandt et al., 1996) .
Members of this class of compound have displayed significant potentiation of the acyclovir inhibitory effect and were also active against acyclovir-resistant strains (Moss et al., 1996b) . These inhibitors have also proven useful in inhibiting the VZV ribonucleotide reductase (Llinas- IC 50 (nm) Brunet et al., 1996) .
HIV proteinase inhibitors. Another example of inhibition of enzyme function brought about by disruption of the protein quaternary structure has been observed for HIV proteinase, where dimerization is essential for active protein. Inhibitors of the dimerization process have been prepared which act as alternatives to active site inhibitors (Schramm et al., 1991) .
HCMV DNA maturation inhibitors. It has been noted above that the previously employed holistic approach to inhibition of viruses in cell culture has given way to the reductionist approach targeting specific enzymes and processes. However, evidence is emerging of the lead generation process 'going full-circle' and using the most productive features of both the holistic and reductionist approaches. Screening in cell culture for antiviral effects led to the identification of lead compounds against HCMV. Their mechanism of action was investigated by culturing the virus in the presence of the inhibitor and observing the generation of resistance. The site of mutation was characterized and led to the identification of the target protein. In principle the reductionist approach using a specific protein assay could now be employed (Underwood et al., 1998) .
Lead Optimization
Lead optimization is another key step in the process of discovering candidates for clinical development. Irrespective of the method used to generate a lead it will rarely possess all the desirable properties and so considerable effort is usually required before structures match their target profile. While, in general, the process of lead optimization requires frequent iterations of the hypothesis-synthesis-activity cycle (Fig. 13) , the tactics for enhancing this process are constantly evolving and examples in the field of antiviral research demonstrate this very well.
Biostructural approach
As noted above, the use of high resolution structural data to generate leads has proven extremely difficult. However, using these data to assist hypothesis generation in the lead optimization phase has been accepted for two decades. Access to multiple inhibitor-enzyme complexes in 'real time' is now a frequent occurrence and this allows the information generated to influence directly the decisions of the medicinal chemist about how to modify current leads. A number of notable successes have resulted, particularly in the field of HIV proteinase inhibitors (Gait & Karn, 1995) . HIV proteinase inhibitors. The first determination of the structure of native HIV proteinase was reported in 1989 . This was rapidly followed by the first structure of an enzyme-inhibitor complex . By 1993 over 160 enzyme-inhibitor complexes had been solved, thus creating a very rich source of data to exploit (Wlodawer & Erickson, 1993) . The first generation proteinase inhibitors were frequently characterized by suboptimum pharmacokinetic profiles. This can be attributed to some extent to their low solubility, high molecular weight, highly peptidic nature and high lipophilicity. Second generation compounds have been prepared following a strategy which focused on modifying these properties. Extensive use was made of the vast amount of structural information which had become available in the interim.
Structural information allowed a highly ordered water molecule to be identified near the active site of the HIV proteinase, bound to isoleucines 50 and 50′ in the two monomers. There are strong thermodynamic arguments for a beneficial effect on binding if this water molecule could be displaced by an inhibitor. A range of cyclic inhibitors were synthesized utilizing the traditional binding sites and the symmetry of the enzyme identified in the earlier substrate-based work. However, additionally, the molecules were extended with the aim of displacing the defined water molecule. Several series of compounds were prepared resulting in the novel and highly potent non-peptidic cyclic urea inhibitors (Fig. 14) (De Lucca et al., 1997) .
Other non-peptidic inhibitors with lower molecular weight have been synthesized using X-ray crystallographic data as a guide. In one notable example the work began by using non-peptidic substructures of the initial substratebased compounds as a starting point. As predicted, this resulted in low potency compounds. However, the researchers then added further moieties to increase binding. They generated crystal structures of inhibitors bound to enzyme at several key steps and used this information to guide the optimization. During the process, changes in binding mode were observed by using the structural information, and the accurate interpretation of these changes was critical for the rapid development of the compounds (Reich et al., 1995) . The compounds prepared during this work demonstrated potent antiviral activity and good oral bioavailability (Fig. 15 ).
High throughput chemistry
In recent years many of the traditional techniques of medicinal chemistry have been supplemented by methods aimed at speeding up the process of generating and optimizing lead compounds. These techniques have included preparing mixtures of compounds and more recently preparing 'discretes' or single compounds using high throughput technology. The preparation of mixtures has evolved to the point where it is principally used for lead generation. However, the preparation of single compounds using parallel synthesizers and/or robotics for rapidly exploring structure-activity relationships has gained considerable momentum. The full impact of the techniques of high throughput chemistry has yet to be seen. The work has been conducted mainly in the industrial sector and as a result specific examples of applications to antiviral drug discovery are still obscured by confidentiality. However there are examples of applications; again HIV proteinase has provided the forum for this work.
HIV proteinase inhibitors. Methodology has been described for synthesizing HIV proteinase inhibitors on solid phase beads (Kick & Ellman, 1995) . The work links the key hydroxyl, crucial for the activity of many of this class of inhibitor, to a resin in a way which allows systematic exploration of other parts of the pharmacophore. The work demonstrates the principal of how solid-phase chemistry, originally conceived for the synthesis of peptides, can be used to prepare small molecule drugs using a range of chemical reactions (Fig. 16 ).
This area is evolving rapidly and the current focus is now away from the preparation of peptides. This is owing to the difficulties in converting these molecules into low molecular weight compounds with acceptable physicochemical properties to make them drugs. More synthetic methods for generating compounds in parallel appear weekly in the chemical literature, and it will be exciting to see the impact made on the drug discovery timelines.
Lead Development
The studies above have illustrated methods of generating lead structures and then optimizing them principally for in vitro activity. Clearly, considerably more optimization will usually be required before the compound is suitable for clinical development.
Pharmacokinetic optimization
Nucleoside inhibitors. Some of the nucleoside analogues suffer from poor pharmacokinetic properties. Acyclovir requires high doses orally or intravenously for some of its effects (Beauchamp et al., 1992) . The principal of generating prodrugs has been used successfully in this area (Higuchi & Stella, 1975) . Use of the valyl ester of acyclovir leads to enhanced bioavailability and an improved clinical profile (Beutner et al., 1995) . The prodrug approach has also been used for penciclovir, which has low oral bioavailability, and this work led to the devel-opment of famiciclovir. Here the free hydroxyls are modified using ester functionality and the base requires in vivo oxidation to give the active entity (Vere Hodge et al., 1989) . Once again, improvements over administration of the parent drug in the clinic have been observed as a result (Fig. 17 ).
An alternative prodrug approach concentrates on avoiding a slow step in the in vivo activation of nucleoside analogues: the preparation of the monophosphate (Fig.  3) . In one example the prodrug is a protected and more stable form of the monophosphate which can be released near the site of action within the cell (Fig. 18 ) Balzarini et al., 1996) .
HIV proteinase inhibitors. Work in the HIV proteinase area also illustrates the advances being made in the understanding of the pharmacokinetics of compounds. Analysis of the structures of marketed, orally available drugs have resulted in guidelines about desirable properties to improve solubility and permeability which may lead to improved oral bioavailability (Lipinski et al., 1997) . Some of these ideas have been incorporated into the design strategies for inhibitors. In the case of VX-478 (Kim et al., 1995) , attempts to reduce the molecular weight and increase solubility of the compound while maintaining potency used information from the crystal structure to minimize the strain energy in the binding conformation. The aims of the work were successfully achieved and led to high blood levels of the active entity after oral dosing (Fig. 19) .
Other methods. The advent of high throughput technologies to screening and chemistry has led to the movement of the bottleneck to the, traditionally, later stages of drug discovery: pharmacokinetics and toxicology. The guidelines, described above, indicate methods are being established to increase the likelihood of molecules having appropriate pharmacokinetic characteristics in vivo. However, this is being supplemented by higher throughput methodology to generate experimental results to guide compound selection. Notable amongst examples of these techniques are the in vitro cultures of intestinal cells where passage of drug has been correlated with oral absorption (Artusson & Borchardt, 1997) . Also, cassette dosing of multiple compounds into animals simultaneously has also demonstrated value as a method of generating results on a range of compounds in a reduced time (Frick et al., 1998) . It is inevitable that these processes will be further developed in the future, leading to an enhancement in the drug discovery process.
Alternative Approaches to Antiviral Therapies
This review has focused on mechanism-based small molecule antivirals, but there are important alternative approaches to the treatment or prevention of viral diseases, such as vaccines (Levine, 1992c) . However, virus mutation means that generation of vaccines is extremely problematic, especially for HIV and HCV (Bartenschlager, 1997) , and it is likely for some viral diseases that vaccination will not play as significant a role. It is especially important in these areas that the focus remains on antiviral therapies.
Immunomodulators
In general, boosting the host antiviral immune response may well lead to beneficial effects, although targeting of the host response rather than the virus leaves a selectivity issue to be addressed. Host organisms to viruses have established finely tuned mechanisms for eliminating virally infected cells. However, it is clear viruses have evolved many meth-ods to avoid detection by the host immune system. Many of these mechanisms are not fully understood but may well provide a rich source of molecular targets in the future.
Imiquimod. This drug (Fig. 20) has recently been approved for the treatment of genital warts after clinical studies demonstrated efficacy after topical application (Beutner et al., 1998) . The mechanism of action appears to be as an inducer of cytokines and it represents a novel approach to low molecular weight drugs for the treatment of viral diseases. Early reports had suggested anti-HSV activity in vivo in guinea pigs for this compound despite a lack of activity in vitro (Harrison et al., 1988) . The compound is a potent interferon inducer and it also induces enhancement of cell-mediated cytolytic activity against HSV-2 targets. The compound has also been found to stimulate other cytokines (tumour necrosis factor, interleukin 6) in mice, as well as interferon α. All of these properties may contribute to its pharmacological activity (Reiter et al., 1994) . Several other approaches have been aimed at boosting the antiviral response. However, most of these involve biopharmaceuticals such as interferons and interleukins, and 
Antisense oligonucleotides
Antisense is another approach used for antiviral therapy. Here, rather than targeting specific proteins for therapeutic effect, the approach is to target the appropriate mRNA. Taking advantage of the rules of nucleotide base pairing it has proved possible to synthesize highly potent and specific oligonucleotides to these targets (Szymkowski, 1996) . Chemical modification of the oligonucleotides, typically at the phosphate linkers, leads to enhanced stability in vivo (Fig. 20) .
Fomivirsen is a phosphorothioate oligonucleotide which has demonstrated very encouraging anti-HCMV activity (Azad et al., 1993) . This entity targets the immediate early gene 2 and is in the late stages of clinical development for the treatment of HCMV retinitis.
Work has also been reported on oligonucleotides targeting the E1 helicase region of papillomaviruses (Lewis et al., 1998) . Here, potent activity was observed in vitro which could be characterized as antisense activity. However, activity in an animal model was not totally accounted for by the antisense mechanism.
Ribozymes
Other approaches based on oligonucleotides are being developed, for example ribozymes (Sullenger, 1995) . Here, cleavage of specific RNA sequences can be observed for oligonucleotides. The problems of delivery are still very significant and it will be interesting to see if these approaches, like antisense, prove to be successful in the clinic.
Aptamers
The development of RNA oligonucleotides to inhibit enzymes directly is making an impact on the drug discovery process. One advantage is that genetic selection strategies can lead to rapid optimization of compounds. Inhibitors of HCV NS3 helicase (Kumar et al., 1997) and HCV NS3 proteinase have been described using this approach. While such compounds will once again have a number of difficulties associated with their delivery they may well find use in niche areas or as tools for drug development.
Outlook
The early successes of nucleoside analogues such as acyclovir have given confidence to scientists to search for and find further novel antivirals such as HIV proteinase and RT inhibitors. These have led to genuine improvements in quality of life and longevity. The immediate future looks exciting with further new classes of therapy such as the influenza virus neuraminidase inhibitors about to emerge on the market.
New targets are still plentiful. Novel viruses are continuing to emerge, many established viruses are still far from satisfactorily controlled and the inevitability of developing resistance to new agents indicates there will be many targets in the future. In the herpesvirus class, human herpesvirus (HHV)-6, -7 and -8 are all recently discovered viruses. In such cases their full role in disease has yet to be determined, but links with established diseases are starting to be formed. Recently it has been suggested that HHV-8 (Chang et al., 1994) has strong links with Kaposi's sarcoma, although a causative relationship still relies on circumstantial evidence. This link was discovered using the technique of representational difference analysis which was used to analyse the genetic differences between infected and uninfected tissue from the same subject. For HHV-6, links have also been reported to multiple sclerosis (Bergstrom, 1998) .
Emergence of resistance appears to occur very rapidly with some viruses. In the herpesvirus area, the US FDA established the Herpes Task Force to analyse the threat of resistance, and for HIV, resistance has resulted in combination treatment being recommended. However, especially for HIV, resistance is becoming better understood at the molecular level (Molla & Kohlbrenner, 1997) . While the relatively low accuracy of the RT has been postulated as a source of the rapid development of resistance, the short replication cycle and the conferring of selective advantage are probably more important . The techniques of molecular biology are leading to the sequences of mutated enzymes and the crystal structures of an inhibitor bound to a mutated enzyme has now been solved . Theories about how the reduced activity caused by mutation may be reversed have been postulated and it is likely that agents specifically designed to overcome these changes will be developed.
Even without high-resolution structural data, factors affecting the generation of resistance are becoming better understood; for example, resistance generated to the HSV ribonucleotide reductase inhibitors has been characterized (White, 1998) .
Demographic changes are also likely to have an effect on the role played by viral diseases. For instance, as the average age of the population increases, multiple episodes of varicella-zoster may become more likely. The likelihood of occurrence will also increase as the use of immunosuppressive therapies rises.
Conclusions
All the available information suggests that the need for effective antiviral drugs will continue to grow. We have seen that the techniques used to produce therapeutic agents have evolved continuously. This process is set to continue. The techniques of high throughput screening and structure-based drug design will be enhanced by high throughput chemistry and coupled with more rapid preclinical evaluation. As a result of these strategies we can expect the rapid development of many novel antiviral agents over the next decade.
